## Satoshi Hattori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/213280/publications.pdf

Version: 2024-02-01

24 papers 128 citations

1477746 6 h-index 10 g-index

24 all docs

24 docs citations

times ranked

24

184 citing authors

#	Article	IF	Citations
1	Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with antiâ€PDâ€I inhibitor. International Journal of Cancer, 2019, 144, 1170-1179.	2.3	29
2	The Effect of Chemotherapy on Stroke Risk in Cancer Patients. Thrombosis and Haemostasis, 2020, 120, 714-723.	1.8	19
3	Estimation of treatment effects based on possibly misspecified Cox regression. Lifetime Data Analysis, 2012, 18, 408-433.	0.4	8
4	Sensitivity analysis for publication bias in metaâ€analysis of diagnostic studies for a continuous biomarker. Statistics in Medicine, 2018, 37, 327-342.	0.8	8
5	Mortality of Japanese Olympic athletes: 1952–2017 cohort study. BMJ Open Sport and Exercise Medicine, 2019, 5, e000653.	1.4	8
6	The Effect of a Cancer History on Patients with Acute Myocardial Infarction After Percutaneous Coronary Intervention. International Heart Journal, 2021, 62, 238-245.	0.5	7
7	Metaâ€analysis of prognostic studies for a biomarker with a studyâ€specific cutoff value. Research Synthesis Methods, 2016, 7, 402-419.	4.2	6
8	Doubly Robust Estimator for Net Survival Rate in Analyses of Cancer Registry Data. Biometrics, 2017, 73, 124-133.	0.8	6
9	Patient-reported burden of symptoms in neuromyelitis optica: A secondary analysis on pain and quality of life. Journal of the Neurological Sciences, 2021, 428, 117546.	0.3	6
10	A confidence interval robust to publication bias for randomâ€effects metaâ€analysis of few studies. Research Synthesis Methods, 2021, 12, 674-679.	4.2	4
11	Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3666-3682.	3.3	4
12	An immature inhibinâ€Î±â€expressing subpopulation of ovarian clear cell carcinoma cells is related to an unfavorable prognosis. Cancer Medicine, 2021, 10, 1485-1500.	1.3	4
13	Time-dependent summary receiver operating characteristics for meta-analysis of prognostic studies. Statistics in Medicine, 2016, 35, 4746-4763.	0.8	3
14	Full Moon and Out-of-Hospital Cardiac Arrest in Japan ― Population-Based, Double-Controlled Case Series Analysis ―. Circulation Reports, 2019, 1, 212-218.	0.4	3
15	Evaluation of predictive capacities of biomarkers based on research synthesis. Statistics in Medicine, 2016, 35, 4559-4572.	0.8	2
16	Environmental factors related to sleep latency among inpatients in rehabilitation wards according to functional independence measure cognitive scores. International Journal of Nursing Practice, 2022, 28, e12964.	0.8	2
17	Association between respiratory and heart rate fluctuations and death occurrence in dying cancer patients: continuous measurement with a non-wearable monitor. Supportive Care in Cancer, 2022, 30, 77-86.	1.0	2
18	Using clinical trial registries to inform Copas selection model for publication bias in metaâ€analysis. Research Synthesis Methods, 2021, 12, 658-673.	4.2	2

#	Article	IF	CITATIONS
19	Distribution of hypomelanotic macules in tuberous sclerosis complex: A retrospective cohort study. Journal of the American Academy of Dermatology, 2022, 87, 237-240.	0.6	2
20	Estimation of the average causal effect via multiple propensity score stratification. Communications in Statistics Part B: Simulation and Computation, 2018, 47, 48-62.	0.6	1
21	Doubly robust inference procedure for relative survival ratio in populationâ€based cancer registry data. Statistics in Medicine, 2020, 39, 1884-1900.	0.8	1
22	Summary concordance index for metaâ€analysis of prognosis studies with a survival outcome. Statistics in Medicine, 2021, 40, 5218-5236.	0.8	1
23	A Change-point Regression Approach for Efficacy Evaluation of Dietary Supplements (P13-017-19). Current Developments in Nutrition, 2019, 3, nzz036.P13-017-19.	0.1	O
24	Sample size calculation for the augmented logrank test in randomized clinical trials. Statistics in Medicine, 2022, , .	0.8	0